Avidity Biosciences

Overview

Biotech using full monoclonal antibody conjugated to oligonucleotides via TFR1 targeting for neuromuscular diseases, acquired by Novartis for $12 billion in 2026, validating commercial potential of antibody-oligonucleotide conjugate platforms. Avidity Biosciences uses a full monoclonal antibody (rather than a Fab) to target TFR1 for delivery of oligonucleotides to muscle, pursuing similar neuromuscular disease indications as Dyne Therapeutics. Avidity Biosciences was acquired by Novartis for approximately $12 billion in 2026, signaling strong commercial confidence in antibody-oligonucleotide conjugate platforms targeting neuromuscular diseases. (Segment 3 (10:00-15:00))